CORDIS - Forschungsergebnisse der EU
CORDIS

Pushing Myc inhibition towards the clinic

Ziel

Deregulation of the Myc oncogene promotes tumorigenesis in most if not all cancers and is often associated with poor prognosis. However, targeting Myc has long been considered impossible because of potential catastrophic side effects in normal tissues. Despite this general assumption, we showed that Myc inhibition displays extraordinary therapeutic benefit in various transgenic mouse models of cancer, and caused only mild, well-tolerated and reversible side effects in normal tissues. For these studies we have employed a dominant negative of Myc, called Omomyc, which we designed and validated, and that is able to inhibit Myc transactivation function both in vitro and in vivo. Omomyc has so far been utilized exclusively as gene therapy and served the purpose of pre-clinically validating the therapeutic impact of systemic Myc inhibition. In this proposal we intend to push such a therapeutic approach further towards the clinic, making use of
1. Omomyc-based Cell Penetrating Peptides (CPPs): a novel, state-of-the-art potential method for directly utilising Omomyc itself (or a similar peptide) as a drug;
2. A new generation of Myc inhibitory small molecules generated by our collaborators at the Roswell Park Cancer Center.
Our study in different mouse models of cancer will provide a comprehensive preclinical validation of such innovative therapies and will potentially boost our therapeutic arsenal against the majority of human cancers

Aufforderung zur Vorschlagseinreichung

ERC-2013-CoG
Andere Projekte für diesen Aufruf anzeigen

Gastgebende Einrichtung

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
EU-Beitrag
€ 1 730 700,00
Adresse
CALLE NAZARET 115-117
08035 Barcelona
Spanien

Auf der Karte ansehen

Region
Este Cataluña Barcelona
Aktivitätstyp
Research Organisations
Hauptforscher
Laura Soucek (Dr.)
Kontakt Verwaltung
Andrés De Kelety Alcaide (Mr.)
Links
Gesamtkosten
Keine Daten

Begünstigte (1)